Paloma Partners Management CO Vertex Pharmaceuticals Inc Transaction History

Paloma Partners Management CO

$3.08 Billion
Q3 2024

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$392.81 - $485.53 $1.06 Million - $1.31 Million	2,700 New	2,700 $1.27 Million
Q3 2023 Nov 14, 2023	SELL	$338.18 - $362.46 $1.09 Million - $1.17 Million	-3,224 Reduced 83.81%	623 $216,000
Q2 2023 Aug 14, 2023	BUY	$314.42 - $351.91 $1.21 Million - $1.35 Million	3,847 New	3,847 $1.35 Million
Q2 2022 Aug 15, 2022	SELL	$234.96 - $292.55 $221,802 - $276,167	-944 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$221.42 - $260.97 $209,020 - $246,355	944 New	944 $246,000
Q4 2021 Feb 14, 2022	SELL	$177.01 - $223.45 $9.37 Million - $11.8 Million	-52,912 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$181.39 - $202.99 $2.76 Million - $3.09 Million	15,217 Added 40.37%	52,912 $9.6 Million
Q2 2021 Aug 16, 2021	BUY	$187.49 - $221.1 $5.67 Million - $6.69 Million	30,237 Added 405.43%	37,695 $7.6 Million
Q1 2021 May 17, 2021	SELL	$207.02 - $241.31 $946,495 - $1.1 Million	-4,572 Reduced 38.0%	7,458 $1.6 Million
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $2.04 Million - $2.71 Million	9,833 Added 447.56%	12,030 $2.84 Million
Q3 2020 Nov 16, 2020	BUY	$255.65 - $303.1 $561,663 - $665,910	2,197 New	2,197 $598,000
Q2 2020 Aug 14, 2020	SELL	$225.48 - $295.8 $541,152 - $709,920	-2,400 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$199.77 - $247.81 $489,436 - $607,134	-2,450 Reduced 50.52%	2,400 $571,000
Q4 2019 Feb 14, 2020	BUY	$166.71 - $223.91 $433,279 - $581,942	2,599 Added 115.46%	4,850 $1.06 Million
Q3 2019 Nov 14, 2019	BUY	$166.23 - $187.09 $374,183 - $421,139	2,251 New	2,251 $381,000
Q2 2019 Aug 14, 2019	SELL	$164.61 - $190.37 $1.34 Million - $1.55 Million	-8,127 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$163.73 - $194.7 $1.33 Million - $1.58 Million	8,127 New	8,127 $1.49 Million
Q4 2018 Feb 14, 2019	SELL	$151.91 - $192.21 $198,242 - $250,834	-1,305 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$167.73 - $192.74 $802,588 - $922,260	-4,785 Reduced 78.57%	1,305 $252,000
Q2 2018 Aug 14, 2018	BUY	$145.72 - $169.96 $9,034 - $10,537	62 Added 1.03%	6,090 $1.04 Million
Q1 2018 May 15, 2018	BUY	$151.6 - $177.13 $153,116 - $178,901	1,010 Added 20.13%	6,028 $982,000
Q4 2017 Feb 14, 2018	SELL	$137.28 - $155.55 $838,094 - $949,632	-6,105 Reduced 54.89%	5,018 $752,000
Q3 2017 Nov 14, 2017	BUY	$148.13 - $162.24 $1.65 Million - $1.8 Million	11,123	11,123 $1.69 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

Capital World Investors Los Angeles, CA

26.8M
Shares

$11 Billion
1.99% of portfolio
Vanguard Group Inc Valley Forge, PA

23.2M
Shares

$9.51 Billion
0.2% of portfolio
Black Rock Inc. New York, NY

21.3M
Shares

$8.75 Billion
0.23% of portfolio
State Street Corp Boston, MA

11.8M
Shares

$4.85 Billion
0.23% of portfolio
Capital Research Global Investors Los Angeles, CA

9M
Shares

$3.7 Billion
0.9% of portfolio

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Paloma Partners Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Paloma Partners Management CO with notifications on news.

Account